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1. Introduction 
Patients with chronic kidney disease and patients on renal replacement therapy, such as 
hemodialysis and peritoneal dialysis, have an increased susceptibility to infectious diseases 
compared with healthy subjects (Sarnak & Jaber 2000; Allon et al. 2003). Infection is also the 
second most common cause of morbidity and mortality in patients with end-stage renal 
disease (Bloembergen & Port 1996; Powe et al. 1999; Graff et al. 2002).  
One contributing factor could be the chronic inflammatory activation seen in patients with 
chronic kidney disease and patients on dialysis, which causes a refractoriness of leukocytes 
when confronted with invading microorganisms. 
1.1 The innate and adaptive immune responses  
The immune system is designed to defend us from invading microorganisms, such as 
viruses and bacteria. The first response is called the innate immune response, mostly 
dependent on recruitment and activation of neutrophils (Parkin & Cohen 2001). 
Complement activation occurs on the bacterial cell surface, triggering a cascade of 
proteolytic reactions that are specific in so far as they act on microbial surfaces but not on 
host cells. Neutrophils have receptors both for common bacterial constituents and for 
complement. Neutrophils become activated through complement (C3b and C5a) but can 
also get activated directly by bacterial peptides, such as lipopolysaccharide, lipotechoic acid, 
mannans and fMLP (N-formylmethionyl leucyl phenylalanine) (Parkin & Cohen 2001).  
Activation of neutrophils occurs in several steps, comprising both priming and further 
activation, and is necessary for neutrophils to perform their specific actions at the 
inflammatory sites: phagocytosis and release of inflammatory mediators (Swain et al. 2002). 
Neutrophils are effector cells of great importance in the innate immune system. An impaired 
neutrophil function leads to several dysfunctions in the defense against invading 
microorganisms. Neutrophils have previously been regarded as wholly differentiated and 
static cells whose function is based on preformed receptors and soluble factors, and solely 
part of the innate immune system. This idea has been challenged by publications that show 
a high gene transcriptional activity following both activation and extravasation (Theilgaard-
Monch et al. 2006). The transcriptional activation occurs at the inflammatory site and 
engages genes involved in multiple neutrophil functions, such as production of reactive 
oxygen species, hydrogen peroxide, cytokines and chemokines (Theilgaard-Monch et al. 
2004; Coldren et al. 2006). Neutrophils direct both innate and adaptive immune responses, 
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by interacting with immune modulating cells (Cohen et al. 2001; Yamashiro et al. 2001; 
Cohen et al. 2003; Theilgaard-Monch et al. 2004). Neutrophil cytokine and chemokine 
production can be an important link between the innate and the adaptive immune 
responses. Cytokine-activated neutrophils produce and release multiple proinflammatory 
cytokines and chemokines, including IL-1, IL-8, monocyte chemotactic protein-1 (MCP-
1/CCL2) and macrophage inflammatory protein-1┙ and 1┚ (MIP-1┙/MIP-1┚). MCP-1 and 
MIP-1┙ act as chemotactic and activating signals for mononuclear cells, especially 
monocytes, and for mobilization of other cell surface molecules involved in the adaptive 
immune response (Yamashiro et al. 2001; Kobayashi 2008).  
Chemokines attract neutrophils and monocytes from the circulation to the 
inflammatory/infectious site by first making the endothelium more adhesive to the 
circulating cells and then through a chemokine gradient through the tissue leading the way 
to the site of inflammation (Janeway & Travers 2005). Circulating monocytes that 
extravasate and get activated rapidly develop into mature macrophages with the principal 
function of phagocyting microorganisms (Janeway & Travers 2005).  
1.2 Adhesion molecules 
The recruitment and accumulation of monocytes and neutrophils at inflammatory sites is an 
essential step in the defense against invading microorganisms. The process of extravasation, 
when leukocytes slip through the endothelial cells and basement membrane into the 
underlying interstitium and further to the inflammatory site requires the expression of 
adhesion molecules on the endothelium. This serves to initiate leukocyte adherence by 
interaction between adhesion molecules on leukocytes and vascular endothelial cells 
(Johnson-Leger et al. 2000; van Buul & Hordijk 2004). The main families of adhesion 
molecules are the intercellular adhesion molecules (ICAMs); integrins, selectins and 
cadherins (calcium-dependent adherins) (Parkin & Cohen 2001).  
The selectins, P-selectin (PADGEM, CD62P) and E-selectin (ELAM-1, CD62E), are 
membrane glycoproteins with a lectin-like domain that binds transiently to oligosaccharide 
molecules on passing leukocytes after cytokine-mediated activation of the endothelial cells. 
CD62L is present on circulating leukocytes (Janeway & Travers 2005). Selectin binding leads 
to tethering, which allows leukocytes to search the endothelium for the presence of 
activating factors. In a second step, leukocytes bind firmly to the endothelium, followed by 
the process of diapedesis (Albelda et al. 1994). The tighter adhesion is mediated by ┚2-
integrins CD11a/CD18 (LFA-1) and CD11b (Mac-1 or CR3) expressed on leukocytes after a 
chemokine-mediated conformational change in the integrins. ┚2-integrins bind to 
intercellular adhesion molecules (ICAM-2 on resting endothelium and ICAM-1 on activated 
endothelium) (Adams & Shaw 1994; Gonzalez-Amaro & Sanchez-Madrid 1999; Janeway & 
Travers 2005). The ┚1- integrin very late antigen-4 (VLA-4) is present principally on 
mononuclear cells, mediating monocyte transmigration by binding to vascular adhesion 
molecules (VCAM-1) on activated endothelial cells (Chuluyan & Issekutz 1993). 
1.3 Leukocyte adhesion and extravasation 
Leukocyte adhesion is made possible by the action of chemokines: small, structurally related 
molecules that interact with G-protein-coupled receptors. They perform activation of 
integrins in order to confer tight adhesion between leukocytes and endothelial cells, and 
promote the migration of adherent leukocytes across the endothelium and through the 
extracellular matrix (Adams & Shaw 1994). Chemokines are small molecules, divided into 
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Fig. 1. Leukocyte adhesion to the endothelium, subsequent extravasation and 
transmigration through a chemotactic gradient in the interstitium towards a site of 
inflammation. 
 
Fig. 2. Neutrophil adhesion, extravasation and transmigration. 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
178 
CXC (┙-chemokines) and CC (┚-chemokines) depending on the positions of two cysteine 
residues (C) relative to other amino acids (X) (Charo & Ransohoff 2006). Chemokines are 
produced by inflammatory cells after stimulation with proinflammatory cytokines or 
bacterial products, and there are both soluble and membrane-bound chemokines, with 
various functions (Parkin & Cohen 2001). Some of the chemokines and cytokines analyzed 
in our study, and their respective functions, are listed in Table 1 and Table 2. 
Leukocyte binding to endothelial cells induces production of signaling molecules in the 
endothelial cells and activation of NADPH oxidase in leukocytes. NADPH oxidase 
promotes production of reactive oxygen species that break down the barrier to leukocyte 
passage between the endothelial cells and through the basement membrane (van Buul & 
Hordijk 2004). PECAM-1 plays an important role in transendothelial migration of 
leukocytes, by inducing phosphorylation of tyrosine in junctional proteins which leads to 
loss of cell-cell adhesion (van Buul & Hordijk 2004).  
When neutrophils extravasate, they produce enzymes (i.e. elastase and other proteases such 
as matrix metalloproteinase-9, MMP-9) that break down extracellular matrix proteins and in 
this way promote leukocyte migration through the interstitium (Hermant et al. 2003).  
The final step of the transmigration is the chemokine concentration gradient, which guides 
leukocytes through the interstitium and towards the inflammatory site. CXCL8 (IL-8) and 
CCL2 (MCP-1) act as chemotactic factors for neutrophils and monocytes, respectively. They 
bind to proteoglycans in the extracellular matrix and to similar molecules on the leukocytes 
(Janeway & Travers 2005).  
Neutrophils and monocytes in blood normally express a low amount of CD11b on their 
surface. Following chemokine-mediated activation of the cells, CD11b is mobilized on the 
cell surface and the molecules are activated in order to display their functions (Adams & 
Shaw 1994; Albelda et al. 1994; Adams & Lloyd 1997; Gonzalez-Amaro & Sanchez-Madrid 
1999). Mobilization of CD11b is important in the process of leukocyte transmigration, 
phagocytosis and complement activation as a response to inflammation/infection (Bainton 
et al. 1987; Borregaard et al. 1987; Miller et al. 1987). 
1.4 Respiratory burst 
The enzyme complex NADPH oxidase promotes the generation of reactive oxygen species 
(e.g. superoxide anions) in leukocytes, in a process referred to as the respiratory burst. 
Respiratory burst is a central mechanism for the leukocyte function of phagocytosis and 
elimination of invading microorganisms (Babior 1999). Superoxide anions are converted to 
hydrogen peroxide in the phagolysosome by the action of superoxide dismutase. In the 
absence of superoxide dismutase, superoxide anions can form the highly aggressive 
oxidative substance peroxynitrite (by reacting with nitric oxide) and hydroxyl radicals 
(Dahlgren & Karlsson 1999; Johnson & Giulivi 2005). 
1.5 Apoptosis 
In early apoptosis, there is a reconformation of the cell membrane, with phosphatidyl serine 
(PS) translocated from the inner surface to the outer leaflet of the cell membrane. 
Fluorescein-conjugated Annexin V binds to PS with high affinity and identifies early 
apoptotic cells. Propidium iodide enters through damaged cell membranes after loss of 
membrane integrity and stains DNA, identifying late stages of apoptosis and secondary 
necrotic cells. PS is identified by phagocytes in the extracellular milieu in order to remove 
the dying cells by phagocytosis. 
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Chemokines  Receptor Functions References 
IL-8 (interleukin-8) CXCL8 IL-8 
receptor ┙ 
and ┚ 
Induces neutrophil 
CD11b/CD18 up-
regulation, transmigration 
and activation. Stimulates 
the release of MMP-
9/NGAL. Binding to the 
receptor causes a 
reconformation of integrins, 
which allows neutrophils to 
bind to the endothelial 
cells. 
(Zeilhofer & Schorr 
2000; Drost & 
MacNee 2002; 
Adams & Lloyd 
1997) 
MCP-1 (monocyte 
chemotactic 
protein-1) 
CCL2 CCR2 Chemotactic factor and 
activator of monocytes and 
macrophages. Produced by 
many different 
inflammatory cells. Induces 
up-regulation of 
CD11b/CD18 and 
facilitates monocyte 
adhesion to endothelial 
cells. Associated with 
chronic and acute 
inflammation, as well as 
with the acute coronary 
syndrome. 
(Adams & Lloyd 
1997; Jiang et al. 
1992; Jiang et al. 
1994; Ikeda et al. 
2002; de Lemos et 
al. 2003; Pawlak et 
al. 2004) 
MIP-1α 
(macrophage 
inflammatory 
protein-1α) 
CCL3 CCR1 and 
CCR5 
Released from monocytes 
after trigging of 
CD11b/CD18. Promotes 
the recruitment of 
inflammatory cells. 
Chemotactic factor for both 
monocytes and neutrophils. 
Activates macrophages by 
up-regulation of 
CD11b/CD18. 
(Rezzonico  et al. 
2001; Adams & 
Lloyd 1997; Ramos 
et al. 2005; Weber 
et al. 2000) 
       
MMP-9/NGAL 
(matrix 
metalloproteinase-9 
in complex with 
neutrophil 
gelatinase- 
associated 
lipocalin) 
    MMP-9 and proteolytic 
enzymes degrade the 
extracellular matrix and 
promote leukocyte 
transmigration. Marker of 
neutrophil activation and 
release of reactive oxygen 
species. Regulates 
chemokine activity by 
cleaving of chemokines and 
cytokines. 
(Yan et al. 2001; 
Alberts et al. 2002; 
Brogden & 
Guthmiller 2002; 
Van Den Steen et 
al. 2003) 
Table 1. Chemokines analyzed in our study and their respective functions. 
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Cytokines   Functions References 
TNF-α (tumor 
necrosis factor-α)
  Produced by macrophages 
and monocytes in acute and 
chronic inflammation. Pro-
apoptotic. Up-regulates 
adhesion molecules on 
endothelial cells. Chemotactic 
factor for monocytes and 
primes cells for phagocytosis. 
Increases vascular 
permeability and 
vasodilatation, promotes 
intravascular coagulation, 
and causes the septic 
syndrome and failure of vital 
organs. 
(Idriss & Naismith 
2000; Janeway & 
Travers 2005) 
IL-6     Inflammatory marker, 
important role in acute 
inflammation and production 
of acute phase proteins from 
the liver. 
(Adams & Lloyd 
1997; Pupim et al. 
2004; Pecoits-Filho et 
al. 2002; Panichi et 
al. 2004) 
Table 2. Cytokines analyzed in our study and their respective functions. 
1.6 Leukocyte dysfunction in chronic kidney disease 
There is a complex state of leukocyte dysfunction in chronic kidney disease patients. The most 
important contributing factors are metabolic and functional abnormalities of leukocytes 
caused by the accumulation of uremic toxins that inhibit leukocyte function. In patients on 
dialysis, another factor influencing leukocyte function is bioincompatibility of the dialysis 
procedure resulting in a dysfunctional inflammatory activation (Lundberg et al. 1994; 
Vanholder et al. 1996; Cohen et al. 2001; Horl 2001; Cohen et al. 2003; Cheung et al. 2008).  
In chronic kidney disease, there is an altered leukocyte adherence to endothelial cells, 
decreased activation of inflammatory cells, impaired phagocytosis and chemotaxis and an 
altered generation of reactive oxygen species and hydrogen peroxide (Gibbons et al. 1990; 
Haag-Weber & Horl 1996b; Horl 2001). Chemokine and cytokine dysregulation in chronic 
kidney disease gives rise to a dysfunctional activation of the immune system (Descamps-
Latscha 1993; Malaponte et al. 2007; Carrero et al. 2008). 
The comorbidity of the patient, such as a state of malnutrition and other chronic diseases, 
also plays an important role in this non-physiological inflammatory activity (Cohen et al. 
1997; Stenvinkel et al. 2000; Pecoits-Filho et al. 2002). A study from our group has 
demonstrated that neutrophils and monocytes from patients with advanced chronic kidney 
disease have an impaired expression of CD11b in the interstitium compared with the 
corresponding cells from healthy subjects (Dadfar et al. 2004b, 2004a). The same result has 
been demonstrated for patients on peritoneal dialysis (Dadfar et al. 2004c). 
1.6.1 Uremic toxins with effects on leukocytes 
There are several uremic toxins that inhibit neutrophil functions, e.g. guanidino compounds, 
granulocyte inhibitory protein I and II, degranulation inhibitory protein I and II (identified 
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as angiogenin and complement factor D), ┢- and ┣-light chains and chemotaxis inhibitory 
protein (Vanholder et al. 1994b; Haag-Weber & Horl 1996a; Kaysen 2001; Horl 2002; Kaysen 
& Kumar 2003; Cohen & Horl 2009b, 2009a).  
1.6.2 Patients on hemodialysis 
Historically, dialysis has contributed to saving many lives over the years. Without dialysis, a 
uremic patient unavoidably goes towards death. However, the life quality of patients on 
dialysis still has to be improved to develop an optimal treatment. In spite of the process in 
the last years to strive towards more biocompatible materials and methods, including high-
flux dialysis treatment, patients on hemodialysis still display a high morbidity and mortality 
in infections (Bloembergen & Port 1996; Powe et al. 1999; Graff et al. 2002). Neutrophil 
dysfunction in dialysis patients is manifested by reduced chemotaxis, adherence, respiratory 
burst and glucose consumption in response to an inflammatory stimulus (Vanholder et al. 
1993b; Vanholder et al. 1993a).  
The dysfunctional state of inflammatory activation seen in dialysis patients could be caused 
by several different factors (Cheung et al. 1989; Haag-Weber et al. 1991; Descamps-Latscha 
1993; Schindler et al. 2001; Carracedo et al. 2002; Horl 2002; Raj et al. 2002; Kosch et al. 2003; 
Koller et al. 2004). Fragments of bacterial products can be present in small amounts in the 
dialysate and enter the circulation by diffusion through the dialysis membrane (Horl 2002). 
These bacterial fragments activate proinflammatory cytokines such as IL-6, TNF-┙ and IL-1. 
There is also direct activation of complement factors and of leukocytes by contact with the 
dialysis membrane. Another aspect is the removal of cytokines and other inflammatory 
markers (lipopolysaccharide fragments, granulocyte inhibitory proteins 1 and 2, IL-1, TNF-
┙) and complement factors (C3a, C5a) by the hemodialysis procedure as well as the 
adsorption of substances to the hydrophobic high-flux membrane (e.g. factor D) (Clark et al. 
1999; Schindler et al. 2006). Dialysis can reduce leukocyte-endothelial interactions and 
impair transmigration (Thylen et al. 1997). In patients on hemodialysis with cuprophane or 
polysulfone membranes, a significantly higher serum level of MCP-1 is seen compared with 
healthy subjects both before and after the hemodialysis session, independent of the 
membrane used (Jacobson et al. 2000; Thylen et al. 2000).  
Biocompatibility of dialysis membranes probably plays an important role in determining 
leukocyte function in patients on hemodialysis (Himmelfarb et al. 1991; Himmelfarb et al. 
1993; Hernandez et al. 2004; Schindler et al. 2006). High serum levels of cytokines and 
chemokines have been observed in patients on hemodialysis with modified cellulose 
membranes (Descamps-Latscha 1993; Pawlak et al. 2004; Muniz-Junqueira et al. 2005). High-
flux hemodialysis causes lower levels of IL-6 and IL-1┚ than low-flux hemodialysis or 
dialysis with cuprophane membranes (Schindler et al. 2006). Our group has previously 
demonstrated that neutrophils and monocytes recruited to an induced interstitial 
inflammatory site in patients treated with low-flux bioincompatible hemodialysis have an 
impaired capacity of mobilizing CD11b in response to the induced inflammation, compared 
with the corresponding cells from healthy subjects (Thylen et al. 2000; Jacobson et al. 2002).  
Chronic kidney disease is a state that induces apoptosis, but this is normalized with 
continuous and high-flux hemodialysis modalities (D'Intini et al. 2004; Bordoni et al. 2006). 
This is in accordance with studies showing that dialysis membrane characteristics affect 
leukocyte cell apoptosis (Martin-Malo et al. 2000; Sela et al. 2005; Sardenberg et al. 2006). The 
degree of spontaneous apoptosis of leukocytes is higher when bioincompatible membranes 
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are used for hemodialysis, than when biocompatible membranes are used (Martin-Malo et 
al. 2000). This higher apoptotic activity in leukocytes is probably due to an antibody-
dependent activation of the complement system caused by the material or structure of the 
dialysis filters. It has been shown that heat-inactivation of complement components results 
in significantly lower apoptosis rates and that bioincompatible membranes cause a higher 
degree of apoptosis than biocompatible membranes (Koller et al. 2004).  
The dialysis membrane permeability and flux are also of importance in determining the 
acute and chronic effects of hemodialysis on the inflammatory system. High-flux 
polysulfone dialysis, as opposed to low-flux polysulfone and cuprophane treatment, has 
been shown to improve the transmigration of circulating neutrophils (Moshfegh et al. 2002). 
High-flux dialysis membranes decrease the levels of the two degranulation inhibitory 
proteins (angiogenin and complement factor D), which could contribute to the maintained 
respiratory burst and phagocytic capacity seen in patients on high-flux hemodialysis (Horl 
2002). There are several molecules, mainly middle-sized molecules, that are cleared to a 
greater extent by convective therapies, such as hemofiltration or hemodiafiltration (Clark et 
al. 1999). Postdilution hemofiltration was the first convective therapy used, and this method 
provides a high clearance of middle- and large-sized molecules but a lower clearance of 
small molecules. Through predilution hemofiltration, with on-line ultrafiltration, the 
clearance of small molecules increased substantially. In hemodiafiltration, convection is 
combined with diffusion, and with this mechanism the clearance of small-, middle- and 
large-sized molecules can be achieved to more or less the same extent (Ledebo 1998).  
A number of previous studies have suggested that the type of dialysis membrane (low-flux 
or high-flux) is associated with differences in long-term outcome of patients undergoing 
hemodialysis, both in terms of morbidity and mortality (Hornberger et al. 1992; Woods & 
Nandakumar 2000; Cheung et al. 2003; Locatelli 2003; Chauveau et al. 2005; Canaud et al. 
2006). However, the results have been conflictive regarding different outcomes. 
The HEMO study, which was the first large randomized clinical trial on patient outcome 
depending on membrane permeability, failed to show any difference in all-cause mortality 
between high-flux and low-flux hemodialysis, except in some subgroups of patients 
(Eknoyan et al. 2002; Cheung et al. 2003; Rocco et al. 2005). Some criticism regarding the 
generalizability of the results from the HEMO study has been raised (Locatelli 2003). 
Important results from the HEMO study indicate that middle-sized molecules, e.g. 
parathyreoid hormone, ┚2-microglobulin, advanced glycosylation end products, granulocyte 
inhibitory proteins, advanced lipoxidation end products, advanced oxidation protein 
products and leptin (Horl 2002) are associated with systemic toxicity and that their 
accumulation predisposes dialysis patients to severe infections. An increased clearance of 
these molecules, e.g. ┚2-microglobulin, by high-flux hemodialysis is associated with a lower 
mortality by infectious disease (Cheung et al. 2008). An increased removal of middle-sized 
molecules could also have positive effects of the cardiovascular system (Vanholder et al. 
2001; Vanholder et al. 2008).  
In a Cochrane database review by Rabindranath et al. in 2006, the authors were unable to 
demonstrate a significant advantage with convective therapies over low-flux hemodialysis 
with regard to clinical outcomes such as mortality, dialysis-related hypotension and 
hospitalization (Rabindranath et al. 2006). 
The DOPPS study (Dialysis Outcomes and Practice Patterns Study) revealed that patients on 
high-flux hemodiafiltration had a 35 % lower mortality rate than patients on low-flux 
hemodialysis (Canaud et al. 2006; Canaud et al. 2008).  
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The MPO-study (Membrane Permeability Outcome) was a European randomized clinical 
trial on the effect of high-flux treatment in a large hemodialysis population. It was a 
prospective study which analyzed the long-term effects of membrane permeability on 
clinical outcomes such as mortality, morbidity, vascular access survival and nutritional 
status. The authors of the MPO-study did not find any significant survival benefit overall by 
high-flux hemodialysis versus low-flux hemodialysis. However, for some dialysis 
populations with low serum albumin and for patients with diabetes mellitus, a significantly 
lower mortality rate was observed using high-flux hemodialysis as compared with low-flux 
hemodialysis (Locatelli et al. 2009). 
2. Leukocyte functional studies in patients on high-flux biocompatible 
hemodialysis 
Our research group has described functions of in vivo extravasated monocytes and 
neutrophils from patients on high-flux hemodialysis/hemodiafiltration and healthy subjects 
(Olsson et al. 2007). The objective was to study leukocyte function and specifically, to study 
the up-regulation of CD11b, production of hydrogen peroxide and apoptosis of in vivo 
extravasated monocytes and neutrophils at the site of an induced interstitial inflammation in 
patients on high-flux hemodialysis/hemodiafiltration, compared with healthy subjects. Our 
group has also described the concentrations of important inflammatory mediators for 
neutrophils (IL-8 and MMP-9/NGAL) and monocytes (MCP-1 and MIP-1┙) in the 
peripheral circulation and at sites of interstitial inflammation in patients on high-flux 
hemodialysis/hemodiafiltration, compared with healthy subjects (Olsson et al. 2009).  
2.1 Methods for leukocyte functional studies 
The method used was the skin chamber technique, which is well documented and has been 
used by a number of investigators to study transmigration and recruitment of leukocytes at 
the inflammatory site (Scheja & Forsgren 1985; Follin 1999; Thylen et al. 2000; Jacobson et al. 
2002; Theilgaard-Monch et al. 2004; Dadfar et al. 2007; Paulsson et al. 2007). With the skin 
chamber technique, we measured leukocyte functions at time 0 (before the high-flux 
hemodialysis/hemodiafiltration session) and after 10 hours (within which time the high-
flux hemodialysis/hemodiafiltration treatment was performed). The terms intermediate and 
intense inflammation were used to designate the blister stimulated with buffer and with 
autologous serum, respectively. 
Leukocytes were measured with flow cytometry or FACS (fluorescence-activated cell 
sorting) a method in which cells are scanned by a laser and recognized as different cell 
populations through their light-scattering properties. Different leukocyte populations 
(lymphocytes, monocytes and neutrophils) can thus be counted and expressed as a 
percentage of the total leukocyte population. Mean fluorescence intensity (MFI) values for 
the different analyses of cell functions (CD11b expression, hydrogen peroxide formation and 
apoptosis) can also be measured and quantified.  
The CD11b expression on leukocytes, both unstimulated and after stimulation with fMLP, 
was studied through immunostaining. Analysis of leukocyte hydrogen peroxide formation, 
after stimulation with fMLP or PMA, was performed using the 2’, 7’-dichlorofluorescein 
diacetate (DCFH-DA) method. We also stained leukocytes with Annexin V and propidium 
iodide (PI) to identify cells that were in an early or late apoptotic state.  
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Chemokines in skin blister fluids and serum from the peripheral circulation were analyzed 
with commercially available immunoassays (Quantikine®, R&D Systems Inc. Minneapolis, 
MN, USA). All immunoassays were used in accordance with the manufacturer’s 
instructions. For further details, please review publications (Olsson et al. 2007 & Olsson et al. 
2009). 
2.2 Results 
2.2.1 CD11b 
There was a similar expression of CD11b on monocytes and neutrophils in patients on high-
flux hemodialysis/hemodiafiltration and healthy subjects, both in the peripheral circulation 
and at the three sites of interstitial inflammation. In vitro activation with fMLP induced a 
significant increase in the expression of CD11b on monocytes and neutrophils in the 
peripheral circulation and at the sites of interstitial inflammation, both in patients on high-
flux hemodialysis/hemodiafiltration and healthy subjects.  
The preserved capacity of both monocytes and neutrophils to express CD11b at the sites of 
interstitial inflammation in patients on high-flux hemodialysis/hemodiafiltration, as shown 
by our findings, may have important biological consequences in terms of an adequate 
performance of leukocyte functions in which the CD11b molecule plays a key role (Thylen et 
al. 1997; Moshfegh et al. 2002). Extravasated neutrophils and monocytes from patients on 
high-flux hemodialysis/hemodiafiltration showed a maintained response to fMLP as a 
second inflammatory stimulus after extravasation.  
The mechanism behind this preserved leukocyte function in patients on high-flux 
biocompatible hemodialysis/hemodiafiltration could be the removal of small and middle-
sized leukocyte inhibitory molecules by high-flux hemodialysis/hemodiafiltration 
(Vanholder et al. 1994a), but membrane compatibility could also play an important role.  
2.2.2 Hydrogen peroxide formation 
Results for hydrogen peroxide production in neutrophils and monocytes are displayed in 
Figures 3-6. The findings indicate the presence of a dose-response phenomenon in terms of 
leukocyte function at the site of interstitial inflammation in patients on high-flux 
hemodialysis/hemodiafiltration, which could be due to leukocyte refractoriness when 
encountered with an intense inflammatory stimulus. Refractoriness of leukocytes could be 
caused by previous priming, giving rise to an impaired response to a second activating 
stimulus. 
2.2.3 Apoptosis and cell counts 
There was no significant difference in the total number of leukocytes at the inflammatory 
sites between patients on high-flux hemodialysis/hemodiafiltration and healthy subjects.  
In our study of leukocytes from patients on high-flux hemodialysis/hemodiafiltration, 
leukocytes were studied at their actual site of action, namely after in vivo extravasation. This 
is advantageous, since leukocyte function in patients with chronic kidney disease or on 
dialysis has previously almost exclusively been studied on cells collected from the 
peripheral circulation. 
In both the neutrophil and monocyte populations, we observed no significant differences in 
the percentage of apoptotic cells (Annexin V+ and Annexin V+ PI+) in the peripheral 
circulation or at the sites of interstitial inflammation between patients on high-flux 
hemodialysis/hemodiafiltration and healthy subjects.  
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Fig. 3. Respiratory burst in neutrophils at the site of an intermediate interstitial 
inflammation expressed as mean fluorescence intensity (MFI). P is indicated where a 
significant difference is present. 
p < 0.001 
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Fig. 4. Respiratory burst (MFI) in neutrophils at the site of intense interstitial inflammation.  
p < 0.05 
p < 0.01 
p < 0.001 
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Fig. 5. Respiratory burst (MFI) in monocytes at the site of intermediate interstitial 
inflammation. No significant difference for any comparison.  
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Fig. 6. Respiratory burst (MFI) in monocytes at the site of intense interstitial inflammation. 
2.2.4 Concentrations of chemokines 
Patients on high-flux hemodialysis/hemodiafiltration had significantly higher 
concentrations of MCP-1, MIP-1┙, IL-6, IL-8, TNF-┙ and high-sensitivity CRP (hsCRP) in the 
peripheral circulation, prior to dialysis treatment, compared with healthy subjects (Olsson et 
al. 2009). MMP-9/NGAL serum concentration was similar in patients on high-flux 
hemodialysis/hemodiafiltration and healthy subjects (Olsson et al. 2009). Significantly 
higher serum levels of ┚2-microglobulin and serum amyloid A (SAA) were observed in 
patients on high-flux hemodialysis/hemodiafiltration, compared with healthy subjects. The 
serum concentrations of chemokines, hsCRP, SAA and oxidized LDL were not influenced by 
the high-flux hemodialysis/hemodiafiltration session, while the concentration of ┚2-
microglobulin was significantly reduced (unpublished data).  
The concentrations of MIP-1┙, MMP-9/NGAL and IL-8 at the sites of intermediate and intense 
inflammation were similar in patients and healthy subjects, and the concentration of MCP-1 at 
the sites of intermediate and intense inflammation was significantly higher in patients on high-
flux hemodialysis/hemodiafiltration, compared with healthy subjects (Olsson et al. 2009). At 
the site of intermediate inflammation, the concentration of IL-6 and TNF-┙ was significantly 
higher in patients compared with healthy subjects, reflecting a high inflammatory activity 
(unpublished data). There were no significant correlations between the concentrations of 
chemokines or the gradient between the concentration in the peripheral circulation and the 
interstitium, and the recruitment of neutrophils and monocytes and their expression of CD11b 
at the site of interstitial inflammation (unpublished data). 
p < 0.05 
p < 0.05 
p < 0.05 
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3. Conclusion 
In vivo extravasated monocytes and neutrophils from patients on high-flux 
hemodialysis/hemodiafiltration have a preserved capacity to mobilize CD11b, compared 
with the corresponding cells from healthy subjects (Olsson et al. 2007). Furthermore, 
monocytes and neutrophils were able to respond to a second signal (fMLP) at the site of 
interstitial inflammation, indicating an adequate response to bacterial peptides (Olsson et al. 
2007). After the most potent stimulation, both monocytes and neutrophils that had 
extravasated in vivo and been recruited to the site of intense inflammation showed a lower 
capacity to produce hydrogen peroxide in response to activation, compared with the 
corresponding cells from healthy individuals (Olsson et al. 2007). The apoptotic rates of 
neutrophils and monocytes were similar in patients and in healthy subjects (Olsson et al. 
2007). Clearance of leukocytes from the site of infection via apoptosis is essential for the 
coordinated resolution of inflammation. The balance between pro-apoptotic and anti-
apoptotic factors is necessary for the maintenance of an effective immune response without 
the harmful side effects of an excessive neutrophil activation.  
The higher concentration of MCP-1 and equal concentration of IL-8, MMP-9/NGAL and 
MIP-1┙ at the sites of intermediate and intense inflammation in patients on high-flux 
hemodialysis/hemodiafiltration (Olsson et al. 2009) could be of importance for the 
maintained capacity of leukocytes to extravasate and mobilize CD11b compared with 
healthy subjects (Olsson et al. 2007). These data contrast with our previous studies on 
patients with chronic kidney disease or patients on peritoneal dialysis, in which the 
concentrations of MCP-1 and IL-8 are significantly lower, coupled with an impaired 
capacity to up-regulate CD11b on neutrophils at sites of interstitial inflammation (Dadfar et 
al. 2004c; Dadfar et al. 2004b, 2004a).  
The results of our study support a preserved neutrophil and monocyte function in terms of 
extravasation and activation at the inflammatory focus. One possible explanation for the 
preserved capacity of monocytes and neutrophils to express CD11b in response to an 
interstitial inflammation in patients on high-flux hemodialysis/hemodiafiltration may be 
that the cells extravasate into a milieu which contains equal or higher concentrations of 
factors involved in transmigration and CD11b expression (MCP-1, IL-8, MIP-1┙ and MMP-
9/NGAL) compared with healthy subjects. The maintained capacity to produce chemokines 
in the interstitium in patients on high-flux hemodialysis/hemodiafiltration may be due to 
an increased intradialytic removal of uremic substances that inhibit leukocyte function. 
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